Cost-utility analysis of genetic screening in families of patients with germline MUTYH mutations

BMC Medical Genetics

Volumn 8, Issue , 2007, Pages

  Nielsen, Maartje ^a   Hes, Frederik J ^a   Vasen, Hans F A ^a,b   van den Hout, Wilbert B ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Foundation for the Detection of Hereditary Tumours   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA GLYCOSYLASE MUTY; DNA GLYCOSYLTRANSFERASE;

ADULT; AGED; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CHILD; CLINICAL ARTICLE; COLONOSCOPY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC COUNSELING; GENETIC SCREENING; GERM LINE; HETEROZYGOSITY; HIDDEN MARKOV MODEL; HUMAN; INTERNATIONAL COOPERATION; MALE; MOLECULAR GENETICS; MUTYH ASSOCIATED POLYPOSIS; NETHERLANDS ANTILLES; OCCULT BLOOD; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; SENSITIVITY ANALYSIS; STANDARDIZATION; COLON POLYPOSIS; COLORECTAL TUMOR; COST BENEFIT ANALYSIS; ECONOMICS; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; MUTATION; NETHERLANDS; PEDIGREE; PROBABILITY;

ADENOMATOUS POLYPOSIS COLI; ADULT; AGED; AGED, 80 AND OVER; CHILD; COLONOSCOPY; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; DNA GLYCOSYLASES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GERM-LINE MUTATION; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; NETHERLANDS; PEDIGREE; QUALITY-ADJUSTED LIFE YEARS;

EID: 34547920290     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-8-42     Document Type: Article

References (45)

1. Al Tassan N Chmiel NH Maynard J Fleming N Livingston AL Williams GT Hodges AK Davies DR David SS Sampson JR Cheadle JP Inherited variants of MYH associated with somatic G:C→ T:A mutations in colorectal tumors Nat Genet 2002 30 2 227-232 10.1038/ng828 11818965
2. Nielsen M Franken PF Reinards TH Weiss MM Wagner A van der KH Kloosterman S Houwing-Duistermaat JJ Aalfs CM Ausems MG Brocker-Vriends AH Gomez Garcia EB Hoogerbrugge N Menko FH Sijmons RH Verhoef S Kuipers EJ Morreau H Breuning MH Tops CM Wijnen JT Vasen HF Fodde R Hes FJ Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP) J Med Genet 2005 42 9 e54 10.1136/jmg.2005.033217 16140997
3. Sampson JR Dolwani S Jones S Eccles D Ellis A Evans DG Frayling I Jordan S Maher ER Mak T Maynard J Pigatto F Shaw J Cheadle JP Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH Lancet 2003 362 9377 39-41 10.1016/S0140-6736(03)13805-6 12853198
4. Gismondi V Meta M Bonelli L Radice P Sala P Bertario L Viel A Fornasarig M Arrigoni A Gentile M Ponz DL Anselmi L Mareni C Bruzzi P Varesco L Prevalence of the Y165C, G382D and 1395delGGA germline mutations of the MYH gene in Italian patients with adenomatous polyposis coli and colorectal adenomas Int J Cancer 2004 109 5 680-684 10.1002/ijc.20054 14999774
5. Bapat B Noorani H Cohen Z Berk T Mitri A Gallie B Pritzker K Gallinger S Detsky AS Cost comparison of predictive genetic testing versus conventional clinical screening for familial adenomatous polyposis Gut 1999 44 5 698-703 1727488 10205208
6. Croitoru ME Cleary SP Di Nicola N Manno M Selander T Aronson M Redston M Cotterchio M Knight J Gryfe R Gallinger S Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk J Natl Cancer Inst 2004 96 21 1631-1634 15523092
7. Gyrd-Hansen D Sogaard J Kronborg O Colorectal cancer screening: efficiency and effectiveness Health Econ 1998 7 1 9-20 10.1002/ (SICI)1099-1050(199802)7:1<9::AID-HEC304>3.0.CO;2-H 9541080
8. Fujita M Sugiyama R Kumanishi Y Ota J Horino T Nakano Y Taguchi T Evaluation of effectiveness of mass screening for colorectal cancer World J Surg 1990 14 5 648-652 10.1007/BF01658816 2238667
9. Allison JE Lawson M Screening tests for colorectal cancer: A menu of options remains relevant Curr Oncol Rep 2006 8 6 492-498 10.1007/ s11912-006-0079-4 17040627
10. Sieber OM Lipton L Crabtree M Heinimann K Fidalgo P Phillips RK Bisgaard ML Orntoft TF Aaltonen LA Hodgson SV Thomas HJ Tomlinson IP Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH N Engl J Med 2003 348 9 791-799 10.1056/NEJMoa025283 12606733
11. Rowley PT Screening for an inherited susceptibility to colorectal cancer Genet Test 2004 8 4 421-430 10.1089/gte.2004.8.421 15684875
12. Webb EL Rudd MF Houlston RS Colorectal cancer risk in monoallelic carriers of MYH variants Am J Hum Genet 2006 79 4 768-771 1592556 16960817 10.1086/507912
13. Visser O 2007 http://www.IKCnet.nl
14. Van Den Hout WB The GAME estimate of reduced life expectancy Med Decis Making 2004 24 1 80-88 10.1177/0272989X03261564 15005957
15. Watson P Lin KM Rodriguez-Bigas MA Smyrk T Lemon S Shashidharan M Franklin B Karr B Thorson A Lynch HT Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members Cancer 1998 83 2 259-266 10.1002/ (SICI)1097-0142(19980715)83:2<259::AID-CNCR9>3.0.CO;2-L 9669808
16. Winawer SJ Zauber AG Ho MN O'Brien MJ Gottlieb LS Sternberg SS Waye JD Schapiro M Bond JH Panish JF Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup N Engl J Med 1993 329 27 1977-1981 10.1056/NEJM199312303292701 8247072
17. Kronborg O Colonic screening and surveillance Best Pract Res Clin Gastroenterol 2001 15 2 301-316 10.1053/bega.2000.0175 11355917
18. Heitman SJ Manns BJ Hilsden RJ Fong A Dean S Romagnuolo J Cost-effectiveness of computerized tomographic colonography versus colonoscopy for colorectal cancer screening CMAJ 2005 173 8 877-881 1247700 16217110
19. Kronborg O Jorgensen OD Fenger C Rasmussen M Randomized study of biennial screening with a faecal occult blood test: Results after nine screening rounds Scand J Gastroenterol 2004 39 9 846-851 10.1080/ 00365520410003182 15513382
20. Faivre J Dancourt V Lejeune C Tazi MA Lamour J Gerard D Dassonville F Bonithon-Kopp C Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study Gastroenterology 2004 126 7 1674-1680 10.1053/j.gastro.2004.02.018 15188160
21. Imperiale TF Ransohoff DF Itzkowitz SH Turnbull BA Ross ME Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population N Engl J Med 2004 351 26 2704-2714 10.1056/ NEJMoa033403 15616205
22. Norum J Vonen B Olsen JA Revhaug A Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma. A cost-effectiveness analysis Ann Oncol 1997 8 1 65-70 10.1023/ A:1008265905933 9093709
23. Whynes DK Neilson AR Robinson MH Hardcastle JD Colorectal cancer screening and quality of life Qual Life Res 1994 3 3 191-198 10.1007/ BF00435384 7920493
24. Van Den Brink M Van Den Hout WB Stiggelbout AM Klein KE Marijnen CA Van De Velde CJ Kievit J Cost-utility analysis of preoperative radiotherapy in patients with rectal cancer undergoing total mesorectal excision: A study of the Dutch Colorectal Cancer Group J Clin Oncol 2004 22 2 244-253 10.1200/JCO.2004.04.198 14665610
25. Oostenbrink JB Bouwmans CAM Koopmanschap MA Rutten FFH Handleiding voor kostenonderzoek; methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. Geactualiseerde versie 2004 College voor zorgverzekeringen Diemen 2004 http://www.cvz.nl
26. Tranmer JE Guerriere DN Ungar WJ Coyte PC Valuing patient and caregiver time: A review of the literature Pharmacoeconomics 2005 23 5 449-459 10.2165/00019053-200523050-00005 15896097
27. Pignone M Rich M Teutsch SM Berg AO Lohr KN Screening for colorectal cancer in adults at average risk: A summary of the evidence for the U.S. Preventive Services Task Force Ann Intern Med 2002 137 2 132-141 12118972
28. Heitman SJ Manns BJ Hilsden RJ Fong A Dean S Romagnuolo J Cost-effectiveness of computerized tomographic colonography versus colonoscopy for colorectal cancer screening CMAJ 2005 173 8 877-881 1247700 16217110
29. Gyrd-Hansen D Sogaard J Kronborg O Colorectal cancer screening: efficiency and effectiveness Health Econ 1998 7 1 9-20 10.1002/ (SICI)1099-1050(199802)7:1<9::AID-HEC304>3.0.CO;2-H 9541080
30. de Visser M van Ballegooijen M Bloemers SM van Deventer SJ Jansen JB Jespersen J Kluft C Meijer GA Stoker J de Valk GA Verweij MF Vlems FA Report on the Dutch consensus development meeting for implementation and further development of population screening for colorectal cancer based on FOBT Cell Oncol 2005 27 1 17-29 15750204
31. Proposal for a Recommendation of the council on cancer prevention Official J Eur Union[2003/878/EC: 34-8] 2003
32. 2007 http://www.CBS.nl
33. Earle CC Chapman RH Baker CS Bell CM Stone PW Sandberg EA Neumann PJ Systematic overview of cost-utility assessments in oncology J Clin Oncol 2000 18 18 3302-3317 10986064
34. Weinstein MC Siegel JE Gold MR Kamlet MS Russell LB Recommendations of the Panel on Cost-effectiveness in Health and Medicine JAMA 1996 276 15 1253-1258 10.1001/jama.276.15.1253 8849754
35. Bell CM Urbach DR Ray JG Bayoumi A Rosen AB Greenberg D Neumann PJ Bias in published cost effectiveness studies: Systematic review BMJ 2006 332 7543 699-703 1410902 16495332 10.1136/bmj.38737.607558.80
36. Eichler HG Kong SX Gerth WC Mavros P Jonsson B Use of cost-effectiveness analysis in health-care resource allocation decision-making: How are cost-effectiveness thresholds expected to emerge? Value Health 2004 7 5 518-528 10.1111/j.1524-4733.2004.75003.x 15367247
37. Ubel PA Hirth RA Chernew ME Fendrick AM What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003 163 14 1637-1641 10.1001/archinte.163.14.1637 12885677
38. 2007 http://www.oecd.org
39. Council for Public Health and Health Care Sensible and sustainable care 2006 http://www.rvz.net/data/download/Advies_DenZ_samenvatting_engels.doc
40. Nielsen M Poley JW Verhoef S Van Puijenbroek M Weiss JM Burger GT Dommering CJ Vasen HF Kuipers EJ Wagner A Morreau H Hes FJ Duodenal carcinoma in MUTYH-associated polyposis coli J Clin Pathol 2006
41. Jenkins MA Croitoru ME Monga N Cleary SP Cotterchio M Hopper JL Gallinger S Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: A population-based case-family study Cancer Epidemiol Biomarkers Prev 2006 15 2 312-314 10.1158/ 1055-9965.EPI-05-0793 16492921
42. Decruyenaere M Evers-Kiebooms G Cloostermans T Boogaerts A Demyttenaere K Dom R Fryns JP Psychological distress in the 5-year period after predictive testing for Huntington's disease Eur J Hum Genet 2003 11 1 30-38 10.1038/sj.ejhg.5200913 12529703
43. Schlich-Bakker KJ Warlam-Rodenhuis CC van Echtelt J van den BJ Ausems MG Ten Kroode HF Short term psychological distress in patients actively approached for genetic counselling after diagnosis of breast cancer Eur J Cancer 2006 16949277
44. Griffith GL Edwards RT Gray J Cancer genetics services: A systematic review of the economic evidence and issues Br J Cancer 2004 90 9 1697-1703 15150621
45. Lejeune C Arveux P Dancourt V Bejean S Bonithon-Kopp C Faivre J Cost-effectiveness analysis of fecal occult blood screening for colorectal cancer Int J Technol Assess Health Care 2004 20 4 434-439 15609792